LIMD1

Across TCGA pan-cancer cohorts, LIMD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LIMD1 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher LIMD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LIMD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

GBM, HNSC, and CCRCC are the cancer types where LIMD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.737	0.887	.004	11	view →
HNSC	DFS	Tertile	II,III,IV	0.899	1.000	.006	8	view →
CCRCC	OS	Median	III,IV	0.821	0.558	.034	7	view →
PDAC	OS	Median	III,IV	0.593	0.862	.027	7	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LIMD1–GBM (OS)

Open the GBM breakdown →